| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Is ImmuCell (NASDAQ:ICCC) stock way too aggressive for baby boomers?
 | By Ellen Johnson | Macroaxis Story |
It appears ImmuCell will continue to recover much faster as its share price surged up 25.50% today. The entity current daily volatility is 4.09 percent, with a beta of 0.3 and an alpha of 0.77 over DOW. As many millenniums are trying to avoid pharmaceutical products, it makes sense to go over ImmuCell a little further and try to understand its current market patterns. We will evaluate why recent ImmuCell price moves suggest a bounce in March.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
ImmuCell currently holds roughly 5.91 M in cash with 1.11 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82. We provide advice to complement the regular expert consensus on ImmuCell. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in ImmuCell, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding ImmuCell along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmuCell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is ImmuCell's Liquidity
ImmuCell financial leverage refers to using borrowed capital as a funding source to finance ImmuCell ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ImmuCell financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to ImmuCell's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of ImmuCell's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between ImmuCell's total debt and its cash.
ImmuCell Gross Profit
ImmuCell Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing ImmuCell previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show ImmuCell Gross Profit growth over the last 10 years. Please check ImmuCell's gross profit and other fundamental indicators for more details.
ImmuCell Correlation with Peers
Investors in ImmuCell can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in ImmuCell. Diversification will allow for the same portfolio return with reduced risk. The correlation table of ImmuCell and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities ImmuCell is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of ImmuCell for more details
Is ImmuCell valued correctly by the market?
ImmuCell is somewhat reliable given 1 month investment horizon. ImmuCell holds Efficiency (Sharpe) Ratio of 0.25, which attests that the entity had 0.25% of return per unit of risk over the last month. Our standpoint towards determining the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-one different technical indicators, which can help you to evaluate if expected returns of 1.02% are justified by taking the suggested risk. Use ImmuCell Downside Deviation of 2.64, risk adjusted performance of 0.1903, and Market Risk Adjusted Performance of 2.79 to evaluate company specific risk that cannot be diversified away.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of ImmuCell. Please refer to our Terms of Use for any information regarding our disclosure principles.